The Pharma Data

MARCH 5, 2021

Key secondary objectives include measures of safety, pharmacokinetics, and anti-tumor activity (i.e. Secondary endpoints include duration of response (DOR), overall survival (OS), safety, and pharmacokinetics (PK). Overall Response Rate (ORR) and Duration of Response, as determined by appropriate histology-specific response criteria).

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Trials Research Laboratories 52

The Pharma Data

OCTOBER 6, 2021

Safety, tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial elixir prefusion F-targeting monoclonal antibody with an extended half- life, in healthy grown-ups. 2019; 10 548. Griffin MP, et al. Antimicrob Agents Chemother. 2017; 61 (3) e01714-16. Yu XQ, et al. Antimicrob Agents Chemother. 2016; 61 (1) e01020-16.

Pharmacokinetics 52

Pharmacokinetics Government Trials Vaccine 52

The Pharma Data

JULY 2, 2023

In 2019, a team of researchers around Marcus Conrad, Director of the Institute of Metabolism and Cell Death at Helmholtz Munich, had already identified the first FSP1-specific inhibitor, known as iFSP1. Notably, during de-differentiation or metabolic rewiring, certain malignant cancer cells acquire an intrinsic vulnerability to ferroptosis.

Therapies 40

Therapies Small Molecule Pharmacokinetics Disease 40

The Pharma Data

DECEMBER 20, 2020

Pending Health Canada’s approval, the Phase 1 trial is designed to test the safety, tolerability and pharmacokinetics of ALS-4 in healthy volunteers. The secondary objective is to assess the pharmacokinetic profile of SAD and MAD of ALS-4 administered orally to healthy subjects. About ALS-4.

Small Molecule 40

Small Molecule Clinical Trials Trials Treatment 40

The Pharma Data

JANUARY 19, 2021

The secondary objective is to assess the pharmacokinetic profile of SAD and MAD of ALS-4 administered orally to healthy subjects. This announcement is not a prospectus within the meaning of the Regulation (EU) n°2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n°2019/980 of 14 March 2019 and n°2019/979 of 14 March 2019.

Small Molecule 52

Small Molecule Clinical Trials Trials Pharmacokinetics 52

PerkinElmer

JANUARY 7, 2022

There are many reasons that promising drug candidates are discontinued, including poor pharmacokinetics, lack of clinical efficacy, and toxicity. Sci Rep 9, 18911 (2019). With around 90% of candidates failing during clinical development, 1 the process is not only long and risky, but also expensive for those involved.

Drugs 52

Drugs Pharmacokinetics FDA Approval Drug Development 52

Drug Target Review

OCTOBER 4, 2023

7 These inhibitors have faced challenges such as dose-limiting toxicity and poor pharmacokinetics, but geldanamycin ADCs have demonstrated increased survival in mice. Cancers 11 , 394 (2019). 161 , 416–432 (2019). 23 , 4854–4865 (2019). DNA damaging agent-based antibody-drug conjugates for cancer therapy. Dragovich PS.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

MARCH 9, 2022

Sanofi and Swedish Orphan Biovitrum AB (publ) (Sobi ® ) (STO:SOBI) today announced positive topline results from the pivotal XTEND-1 Phase 3 study evaluating the safety, efficacy and pharmacokinetics of efanesoctocog alfa (BIVV001) in previously treated patients ?12 12 years of age with severe hemophilia A.

Treatment 52

Treatment Pharmacokinetics Therapies FDA 52

The Pharma Data

JULY 6, 2021

Population pharmacokinetic and pharmacodynamic modeling data to characterize the antithrombin (AT) lowering dynamics in hemophilia patients treated with fitusiran will be shared in a poster presentation. These data support the revised fitusiran dose and dosing regimen implemented in the ongoing adult and adolescent studies. a Sanofi Company.

Pharmacokinetics 52

Pharmacokinetics Therapies RNA Treatment 52

The Pharma Data

JANUARY 17, 2021

The companies announced in January 2019 a collaboration agreement to develop, manufacture and commercialize SPR206 in the Territory. Spero plans to initiate additional Phase 1 studies to assess the penetration of SPR206 into the pulmonary compartment and pharmacokinetics in subjects with renal impairment in 2021. SHANGHAI , Jan.

Clinical Trials 52

Clinical Trials Clinical Development Pharmacokinetics Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 27, 2020

Risdiplam was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2019 employed about 98,000 people worldwide. In 2019, Roche invested CHF 11.7

Pharmacokinetics 52

Pharmacokinetics FDA Approval Treatment Clinical Trials 52

FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

In 2019, FDA formed an agency-wide Alternative Methods Working Group indicating that it viewed the applicable scope of alternative methods to go beyond just toxicology research. 42 U.S.C. § 262(k)(2)(A)(i)(I).

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays FDA 64

The Pharma Data

AUGUST 22, 2021

Safety, Tolerability, and pharmacokinetics of MEDI8897, the respiratory syncytial virus prefusion F-targeting monoclonal antibody with an extended half-life, in healthy adults. 2019; 10: 548. Griffin MP, et al. Antimicrob Agents Chemother. 2017; 61(3): e01714-16. Yu XQ, et al. Antimicrob Agents Chemother. 2016; 61 (1): e01020-16.

Trials 52

Trials Pharmacokinetics Virus Vaccine 52

The Pharma Data

NOVEMBER 8, 2020

The resubmission came after a meeting with the FDA in February 2020 and addresses issues raised by the agency’s Complete Response Letter (CRL) in November 2019. “We The NDA was resubmitted on May 2020. We have been encouraged by our interactions with the FDA following our CRL and are pleased to resubmit our Zimhi NDA,” said Dennis J.

FDA 52

FDA Trials Pharmacokinetics Pharmaceuticals 52

The Pharma Data

DECEMBER 13, 2020

The companies filed in December 2019, and included analytical, pharmacokinetic and clinical data, as well as pharmacology and toxicology data from two clinical trials. The biosimilar is a collaboration between Amgen and Allergan, which was formed when Allergan was Watson Pharmaceuticals in December 2011.

FDA 52

FDA Biosimilars Clinical Trials Licensing 52

The Pharma Data

FEBRUARY 25, 2022

The study met its primary goal by demonstrating pharmacokinetic equivalence in patients who switched multiple times between treatment with the two medicines. The company anticipates submitting study results for presentation at an upcoming medical congress.

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

New Drug Approvals

OCTOBER 24, 2023

June 2019). . | twitter +919321316780 call whatsaapp EMAIL. “Velsipity (etrasimod) tablets, for oral use” (PDF). . “Modulation of sphingosine-1-phosphate in ulcerative colitis” Expert Opin Biol Ther. 20 (4): 413–420. doi : 10.1080/14712598.2020.1732919. PMID 32093531. ^ 369 (3): 311–317. doi : 10.1124/jpet.118.254268.

FDA 57

FDA FDA Approval International Pharmacokinetics 57

Agency IQ

JULY 28, 2023

During the COVID-19 pandemic, the number of opioid-involved deaths climbed sharply, with mortality rates increasing by 38% between 2019 and 2020. The second wave aligned with an increase in deaths involving heroin, which was followed by a third wave of increased mortality associated with synthetic opioids like illicitly manufactured fentanyl.

FDA 40

FDA Pharmacokinetics Clinical Pharmacology Government 40

Molecular Design

MARCH 26, 2024

With apologies to Manfred Eigen (1927 - 2019) I've just returned to Cheshire from the Caribbean and, to kick off blogging from 2024 I'll share a photo of the orchids at Berwick-on-Sea on the north coast of Trinidad. A theory has only the alternative of being true or false. A model has a third possibility: it may be true, but irrelevant.

Pharmacokinetics 102

Pharmacokinetics Cell Based Assays Drugs Engineering 102

Agency IQ

FEBRUARY 23, 2024

Since 2019, more than half of the population of Europe has been classified as overweight or obese. According to Eurostat, the prevalence of overweight and obesity in adults in 2019 (the most recent year with complete data) was 53%. The figures are lower for individuals meeting obesity criteria , with 2019 data showing just 16.3%

Drugs 40

Drugs Clinical Trials Pharmacokinetics Drug Development 40

The Pharma Data

NOVEMBER 4, 2020

million as of December 31, 2019. million for the same period in 2019. million for the same period in 2019. per share, for the quarter ended September 30, 2019. 2019. 2019. December 31, 2019. December 31, 2019.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Trials Small Molecule 52

The Pharma Data

FEBRUARY 25, 2021

FIREFISH, an open-label, two-part pivotal study, was designed to assess Evrysdi safety, tolerability, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) in patients aged 1 to 7 months with Type 1 SMA. Part 1 evaluated several doses of Evrysdi and determined the therapeutic dose of 0.2 mg/kg for Part 2.

Pharmacokinetics 52

Pharmacokinetics FDA Approval Treatment Disease 52

The Pharma Data

NOVEMBER 18, 2020

This Phase 1 trial will evaluate the safety, tolerability, and pharmacokinetics of SEFA-1024 in 96 otherwise healthy volunteers with elevated plasma triglyceride levels. A Phase 2b study was initiated in July 2019 (ICONA) to study the efficacy of icosabutate in NASH.

Trials 40

Trials Engineering Pharmacokinetics Therapies 40

The Pharma Data

MARCH 16, 2021

Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. At this time, Evrysdi has been approved in seven countries and submitted in 57, including the EU 27 and Norway and Iceland. The study met its primary endpoint.

Pharmacokinetics 52

Pharmacokinetics Clinical Trials Treatment Disease 52

Alta Sciences

APRIL 17, 2024

Ketamine is a dissociative anesthetic approved in 2019 by the U.S. The theory is that if the brain settles into this state, some of the circuitry responsible for depression or anxiety may be altered and reform around a new perspective. Food and Drug Administration (FDA) as a nasal spray called esketamine, for treatment-resistant depression.

Drug Development 52

Drug Development Treatment FDA Approval Therapies 52

Drug Discovery World

AUGUST 10, 2022

Measuring the pharmacokinetics of CAR T cells. 2019) 18: 125. 2019) 3, 1-9. Compared to qPCR, this ddPCR assay has a lower limit of detection (10 copies per microlitre) and reduces hands-on time and human error by removing the need for a standard curve 18. Molecular Therapy. 2010) 18(4):843–851. 9: S Yu, M Yi, S Qin et al.

Therapies 246

Therapies Virus Treatment Engineering 246

The Pharma Data

JANUARY 26, 2021

Previous human pharmacokinetic (PK) study showed significantly better PK profile when compared to market leading product. Total net sales for 2019 amounted to SEK 844.8 Patent protection until 2039. UPPSALA, Sweden , Jan. million and the number of employees was 127.

Pharmacokinetics 52

Pharmacokinetics Drugs Production FDA 52

The Pharma Data

JANUARY 4, 2021

Cell 2019 ). Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2019, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

Drugs 52

Drugs Pharmacokinetics Cell Biology Clinical Trials 52

The Pharma Data

MARCH 30, 2021

Evrysdi was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation in 2019. This approval is applicable to all 27 European Union member states, as well as Iceland, Norway, and Liechtenstein. The study met its primary endpoint. The study has completed recruitment (n=174).

Treatment 52

Treatment Pharmacokinetics Clinical Trials Trials 52

The Pharma Data

OCTOBER 27, 2020

2019. 2019. million for the three months ended September 30, 2020 , compared to the same period in 2019. In addition, as previously disclosed, our 2019 revenues were impacted by a mistake by one of our U.S. million in total, during the third quarter of 2019. 2019.

FDA 40

FDA Production Licensing Licensing 40

The Pharma Data

DECEMBER 3, 2020

Safety and Pharmacokinetics of Antisense Oligonucleotide STK-001 in Children and Adolescents with Dravet Syndrome: Single and Multiple Ascending Dose Design for the Open-Label Phase 1/2a MONARCH Study. The primary endpoints are safety, tolerability and pharmacokinetic (PK) profile of STK-001 in Dravet syndrome patients. About STK-001.

Protein Expression 52

Protein Expression Clinical Trials Pharmacokinetics Trials 52

The Pharma Data

DECEMBER 21, 2020

As UNITY reported in its press release, this “Phase I, first-in-human, open-label, single-ascending dose study being conducted by UNITY is designed to evaluate the safety, tolerability, and pharmacokinetics of UBX1325 in patients with advanced DME. Ascentage Pharma (6855.HK)

Clinical Development 40

Clinical Development Disease Treatment Licensing 40

The Pharma Data

SEPTEMBER 26, 2021

The positive CHMP opinion was supported data from pharmacokinetic bridging studies comparing VUMERITY and TECFIDERA® (dimethyl fumarate) to determine bioequivalent exposure of monomethyl fumarate, the active metabolite, and relied partially on the well-established long-term safety and efficacy profile of TECFIDERA. for TECFIDERA.

Treatment 40

Treatment Clinical Trials Virus Pharmacokinetics 40

The Pharma Data

JUNE 28, 2021

From November 2016 to June 2019, a total of 112 participants were enrolled across 36 sites in 10 countries. UNIVERSE was conducted in two parts.

FDA 52

FDA Clinical Trials Treatment Therapies 52

Drug Target Review

JULY 12, 2023

The goal of DCI in preclinical and clinical assessments is to achieve a manyfold higher drug free-fraction pharmacokinetic (PK) C max level (the plasma concentration of therapy in a specific area of the body) to break tumour addiction to the MAPK signalling pathway followed by a rapid drop off of drug levels enabled by a short plasma half-life.

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

The Pharma Data

DECEMBER 9, 2020

The open-label Phase 2a ‘AMBITION’ study is designed to assess safety, tolerability, pharmacokinetics and biomarker analyses for early assessments of efficacy of 75 mg and 225 mg CRV431, administered orally to F2 and F3 NASH patients (n=18/dosing group), once daily for 28 days.

Clinical Trials 40

Clinical Trials Pharmaceuticals Trials Pharmacokinetics 40

The Pharma Data

JULY 11, 2021

The complete results were based on data collected between May 2016 and October 2019 and included 109 rollover patients who were originally evaluated in the HELP Study, and 103 eligible non-rollover patients who did not participate in the initial study but had experienced at least one HAE attack within the previous 12 weeks. Interactions.

Treatment 52

Treatment Pharmacokinetics Production Disease 52